Johnson & Johnson to spend $500 Million over four years into terminating the epidemic of Tuberculosis and HIV

On Friday, Johnson & Johnson announced that it would spend over 500 million dollars in research and development over the next four years to accelerate the efforts of the world to eliminate tuberculosis (TB) and HIV by 2030. Being one of the leading healthcare companies, Johnson & Johnson is working closely with the government and its partners to improve the health and overall well-being of people around the globe.

Vice-Chairman of the Executive Committee and Chief Scientific Officer and MD of Johnson & Johnson said, “No single institution can tackle the historic challenge of eliminating an infectious disease.” He also added that “By advancing our technologies, uniting our best scientists and leveraging decades of experience in HIV and TB, we’re optimistic that we can make a significant contribution to the global effort.”

Tuberculosis

In 2012, Bed aquiline the first TB medicine as a product of novel dedication for almost half a century was introduced by Janssen. Since then, J&J has provided nearly 150,000 multidrug-resistant TB (MDR-TB) treatment courses to the patients in 131 countries. Global Head of the Global Public Health – Johnson & Johnson, Jaak Peeters, said, “TB is the world’s number one infectious killer, and TB and MDR-TB cause major devastation for people, communities and entire countries around the world.” He also added “The good news is TB is both preventable and treatable, and Johnson & Johnson is committed to doing everything we can to make TB history”.

HIV

J&J has been fighting HIV for more a quarter-century now. Over time, the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) has introduced eight HIV medicines. These medicines include five combination products and three antiviral agents, which make HIV a chronic and manageable disease. Hence allowing millions with HIV to live a healthy life. MD, Global Therapeutic Area Head, Vaccines, and Managing Director, Janssen Vaccines & Prevention B.V., Janssen Pharmaceutica NV, Johan Van Hoof, said “Although HIV is now considered a chronic and manageable condition, people living with HIV still face a lifetime of taking daily pills. We therefore must continue to advance important innovations to help them.”

About Johnson & Johnson

Johnson believes in good health, and it finds its foundation in vibrant lives, thriving communities and forward progress. Company is serving people from the past 130 years and is helping them to be well at every age and every stage of life. Today it is one of the world’s largest and most broadly-based healthcare company. The company committed to using its reach and size for a larger social good. The company strive to improve affordability and access, to make communities healthier, and maintain a healthy mind, body and environment within reach of everyone and everywhere.